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Introduction: TNFAIP3 interacting protein 1, TNIP1 (ABIN-1) is involved in inhibition of nuclear factor-B (NF-B)
activation by interacting with TNF alpha-induced protein 3, A20 (TNFAIP3), an established susceptibility gene to
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Recent genome-wide association studies revealed
association of TNIP1 with SLE in the Caucasian and Chinese populations. In this study, we investigated whether the
association of TNIP1 with SLE was replicated in a Japanese population. In addition, association of TNIP1 with RA
was also examined.
Methods: A case-control association study was conducted on the TNIP1 single nucleotide polymorphism (SNP)
rs7708392 in 364 Japanese SLE patients, 553 RA patients and 513 healthy controls.
Results: Association of TNIP1 rs7708392C was replicated in Japanese SLE (allele frequency in SLE: 76.5%, control:
69.9%, P = 0.0022, odds ratio [OR] 1.40, 95% confidence interval [CI] 1.13-1.74). Notably, the risk allele frequency in
the healthy controls was considerably greater in Japanese (69.9%) than in Caucasians (24.3%). A tendency of
stronger association was observed in the SLE patients with renal disorder (P = 0.00065, OR 1.60 [95%CI 1.22-2.10])
than in all SLE patients (P = 0.0022, OR 1.40 [95%CI 1.13-1.74]). Significant association with RA was not observed,
regardless of the carriage of human leukocyte antigen DR b1( HLA-DRB1) shared epitope. Significant gene-gene
interaction between TNIP1 and TNFAIP3 was detected neither in SLE nor RA.
Conclusions: Association of TNIP1 with SLE was confirmed in a Japanese population. TNIP1 is a shared SLE
susceptibility gene in the Caucasian and Asian populations, but the genetic contribution appeared to be greater in
the Japanese and Chinese populations because of the higher risk allele frequency. Taken together with the
association of TNFAIP3, these observations underscore the crucial role of NF-B regulation in the pathogenesis of SLE.
Introduction
TNFAIP3 (tumor necrosis factor a-induced protein 3)
encodes a ubiquitin-editing protein, A20, known as an
inhibitor of nuclear factor-B( N F - B). Several adaptor
molecules are thought to associate with A20 and be
involved in inhibition of NF-B[ 1 ] .T N I P 1( T N F A I P 3
interacting protein 1), also known as ABIN (A20-bind-
ing inhibitor of NF-B)-1, is one such adaptor molecule
binding to A20. TNIP1 mRNA is strongly expressed in
peripheral blood lymphocytes, spleen and skeletal mus-
cle, and the expression is also detected in kidney [2].
TNIP1 expression is induced by NF-B, and in turn,
overexpression of TNIP1 inhibits NF-B activation by
TNF [1], although deficiency of TNIP1 has few effects
on NF-B inhibition [3]. Thus, TNIP1 appears to play a
* Correspondence: tsuchiya-tky@umin.ac.jp
1Molecular and Genetic Epidemiology Laboratory, Doctoral Program in Life
System Medical Sciences, Graduate School of Comprehensive Human
Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575,
Japan
Full list of author information is available at the end of the article
Kawasaki et al. Arthritis Research & Therapy 2010, 12:R174
http://arthritis-research.com/content/12/5/R174
© 2010 Kawasaki et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.role in NF-B inhibition, at least partly by interacting
with A20. In addition, TNIP1 was shown to inhibit
TNF-induced apoptosis independently of A20 [3].
TNFAIP3, located at 6q23, has been identified as a
susceptibility gene for both systemic lupus erythemato-
sus (SLE) and rheumatoid arthritis (RA) in Caucasian
and Asian populations [4-8]. Recently, Shimane et al. [9]
replicated association of TNFAIP3 single nucleotide
polymorphisms (SNPs) with SLE and RA in a Japanese
population. We also detected association of TNFAIP3
rs2230926 with Japanese SLE patients in an independent
study [10].
Recently a genome-wide association study (GWAS)
reported association of TNIP1 (5q32-q33.1) as well as
TNFAIP3 SNPs with psoriasis in the Caucasian popula-
tions [11]. Subsequently, two recent GWAS revealed
association of TNIP1 intronic SNPs rs7708392 and
rs10036748, which are in strong linkage disequilibrium
(LD) with SLE in the Caucasian (European-American
and Swedish) and Chinese Han populations, respectively
[8,12]. These observations underscored the role of the
pathway involving TNFAIP3-TNIP1 in the genetic pre-
disposition to SLE. The association of TNIP1 with SLE
needs to be further confirmed.
Recently, it has become increasingly clear that SLE
and RA share a number of susceptibility genes.
TNFAIP3 [4-10], STAT4 [13,14] and BLK [15,16] repre-
sent such shared susceptibility genes. TNIP1 has been
shown to be upregulated in synovial tissues from RA
[17], raising a possibility that TNIP1 may also play a
role in the pathogenesis of RA. To date, association of
RA with TNIP1 has not been reported.
This study was conducted to examine whether TNIP1
was associated with SLE and RA in a Japanese population.
Materials and methods
Patients and controls
Three hundred sixty-four Japanese patients with SLE (21
males and 343 females, mean ± SD age, 42.8 ± 13.9
years), 553 patients with RA (43 males and 510 females,
mean ± SD age, 58.0 ± 11.3 years) and 513 healthy con-
trols (238 males and 275 females, mean ± SD age, 34.1 ±
9.9 years) were recruited at University of Tsukuba, Jun-
tendo University, Sagamihara National Hospital, Matsuta
Clinic and the University of Tokyo (Table 1). All patients
and healthy individuals were native Japanese living in the
central part of Japan. All patients with SLE and RA ful-
filled the American College ofR h e u m a t o l o g yc r i t e r i af o r
SLE [18] and RA [19], respectively. Consecutive patients
ascertained in rheumatology specialty hospitals or clinics
were recruited. The patients with SLE were classified into
subgroups according to the presence or absence of renal
disorder, neurologic disease and serositis based on the
definition of ACR criteria [18], anti-dsDNA and anti-Sm
antibodies, and age of onset (< 20 yr). The numbers of
the missing data were 5 (renal disorder), 3 (neurologic
disease), 21 (serositis), 19 (anti-dsDNA antibody), 22
(anti-Sm antibody) and 6 (age of onset). Patients with RA
and healthy controls were stratified by the presence or
absence of human leukocyte antigen DR b1( HLA-DRB1)
shared epitope. The numbers of the missing data were
6 (RA) and 15 (controls).
The control group consisted of healthy volunteers
without any signs or symptoms of autoimmune diseases
recruited at the same institutes.
This study was carried out in compliance with the
Helsinki Declaration. The study was reviewed and
approved by the research ethics committees of the Uni-
versity of Tsukuba, Sagamihara National Hospital and
Juntendo University. Informed consent was obtained
from all study participants.
Genotyping
Genotyping of TNIP1 rs7708392 was carried out using
the TaqMan genotyping assay (Applied Biosystems, Fos-
ter City, CA, USA), according to the manufacturer’s
instructions, using a TaqMan probe C__29349759_10.
HLA-DRB1 was genotyped at the sequence level using a
polymerase chain reaction (PCR) microtiter plate hybri-
dization assay as previously described [20].
Statistical analysis
A case control association study was conducted by c
2 test
using 2 × 2 contingency tables. The null hypotheses tested
in this study were that there was no difference in the geno-
type or allele frequencies between all SLE patients and
healthy controls, between SLE subsets and healthy controls,
between all RA patients and all healthy controls, or
between RA patients and healthy controls stratified by the
presence or absence of HLA-DRB1 shared epitope.
The power to detect association was calculated on the
basis of the frequency of the rs7708392C allele in Japa-
nese healthy controls (69.9%). The sample size of this
study (364 SLE patients, 553 RA patients and 513 con-
trols) had the power of 80% to detect association when
the genotype relative risk was1.36 (SLE) and 1.32 (RA)
or greater, respectively [21].
To adjust for the gender difference between patients
and healthy controls (Table 1), multiple logistic
Table 1 Characteristics of the patients and healthy
controls studied
SLE RA Healthy controls
n 364 553 513
Male/female 21/343 43/510 238/275
Age* 42.8 ± 13.9 58.0 ± 11.3 34.1 ± 9.9
*Mean ± SD.
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used as independent variables: for the genotypes of
rs7708392, C/C = 1, C/G = 0, G/G = 0 under the reces-
sive model for the C allele, C/C = 2, C/G = 1, G/G = 0
under the codominant model, and for gender, male = 0,
female = 1.
The interaction between TNIP1 rs7708392 and
TNFAIP3 rs2230926, which we recently replicated to be
associated with SLE [10], was examined in 308 SLE, 372
RA and 449 healthy controls, using logistic regression
analysis. Codominant (risk allele homozygotes xi =2 ,
heterozygotes xi = 1, nonrisk allele homozygotes xi =0 ) ,
dominant (risk allele homozygotes xi = 1, heterozygotes
xi = 1, nonrisk allele homozygotes xi = 0) and recessive
(risk allele homozygotes xi = 1, heterozygotes xi =0 ,
nonrisk allele homozygotes xi =0 )m o d e l sf o rg e n ei
were tested. The logistic regression model for interac-
tion between gene i and gene j was given by logit(P)=
b0 + bixi + bjxj + bijxixj. The deviation from 0 was eval-
uated for bij by the Wald test. Population attributable
risk percentage (PAR%) was estimated by the formula:
PAR% Pe (RR 1)/(Pe [RR 1] 1) 100 =− − + × ,
where Pe represents the risk genotype frequency in
the population and RR represents the relative risk of the
risk genotype [22]. Although RR cannot be determined
from the case-control study design, it can be approxi-
mated by odds ratio (OR) when the incidence of the dis-
ease is sufficiently low. Because the incidence of SLE has
been reported to be 3.0 in Japan and 1.8-7.6 in the Uni-
ted States per 100,000 persons per year [23] and is suffi-
ciently small, OR can be adequately used for an
approximation for RR. The PAR% in the Caucasian
populations were calculated using the raw genotype
count data for the previously reported study (cases: C/C
293, C/G 1,389, G/G 1,632, controls: C/C 735, C/G
4,510, G/G 7,050) [12].
Results
Replication of TNIP1 association with SLE in Japanese
The association of TNIP1 rs7708392 with SLE, recently
demonstrated in the Caucasian (European-American
and Swedish) populations [12], was examined in a Japa-
nese population. Departure from Hardy-Weinberg equi-
librium was observed neither in the cases nor in the
controls (P > 0.3). As shown in Table 2, rs7708392C
allele was significantly increased in Japanese SLE
patients (76.5%) compared with healthy controls (69.9%,
P = 0.0022, OR 1.40, 95% confidence interval [95% CI]
1.13-1.74), confirming the association in the Caucasians.
The association was also detected under the recessive
model for the rs7708392C allele (P = 0.0023, OR 1.52,
95% CI 1.16-2.00). Notably, the risk allele frequency was
considerably greater in the Japanese (69.9%) than in the
Caucasian healthy controls (24.3%) [12]. In the Japanese,
PAR% was estimated to be 20.4% under the recessive
model for the C allele (OR 1.52, population frequency of
C/C 48.9%) and 31.0% under the dominant model (OR
1.50, population frequency of C/C + C/G 90.8%). These
estimates were substantially greater than in the Cauca-
sian populations, where the PAR% was 3.0% under the
recessive model (OR 1.53, population frequency of C/C
6.0%) and 14.1% under the dominant model (OR 1.39,
population frequency of C/C + C/G 42.7%).
Because the female-to-male ratio was different
between SLE patients and healthy controls (Table 1), we
carried out multiple logistic regression analysis to exam-
ine the association after adjustment for gender. The
association with SLE remained significant both under
the recessive model for rs7708392C (P = 0.030, OR 1.40,
95% CI 1.03-1.89) and under the codominant model
(P = 0.033, OR 1.30, 95% CI 1.02-1.65).
Association of TNIP1 with Clinical Subsets of SLE
We next analyzed whether TNIP1 was associated with
clinical subsets such as presence or absence of renal disor-
der, neurological disease, serositis, anti-dsDNA antibody,
anti-Sm antibody, as well as the age of onset (< 20 yr).
When the association was tested between patients having
each phenotype and healthy controls, a tendency of stron-
ger association was observed in the subsets with renal
disorder and anti-dsDNA antibody as compared with all
SLE (Table 2). These associations remained significant
after adjustment for gender using logistic regression analy-
sis (nephropathy positive versus controls: P = 0.0070, OR
1.50, 95% CI 1.12-2.01 under the codominant model and
P = 0.011, OR 1.59, 95% CI 1.11-2.26 under the recessive
model; anti-dsDNA positive versus controls: P =0 . 0 3 3 ,
OR 1.32, 95% CI 1.02-1.71 under the codominant model
and P = 0.024, OR 1.45, 95% CI 1.05-2.00 under the reces-
sive model).
On the other hand, significant association was not
observed in the patient subsets having neurologic dis-
ease, serositis, anti-Sm antibody, and the patients with
the age of onset <20 yr.
Lack of Association with RA
We next tested association of TNIP1 rs7708392 with
RA. Although a slight tendency toward association was
observed, significant association with RA was not
detected (Table 3). Significant association was not
detected after the adjustment for gender (P =0 . 8 4 7 ,
OR 1.02, 95% CI 0.83-1.26 under the codominant
model, P = 0.753, OR 1.04, 95% CI 0.80-1.36 under the
recessive model), nor after stratification according to
the presence or absence of HLA-DRB1 shared epitope
(Table 3).
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and TNIP1
Finally, we examined whether genetic interaction exists
between TNFAIP3 and TNIP1 SNPs, because molecular
i n t e r a c t i o ni sk n o w nb e t w e e nt h ep r o t e i np r o d u c t so f
these genes. Although all combinations of the codomi-
nant, dominant and recessive models for each gene were
examined, statistically significant gene-gene interaction
was not detected (P> 0.05).
Discussion
In the present study, we replicated the association of
TNIP1 rs7708392 with SLE in a Japanese population,
which indicated that TNIP1, as well as TNFAIP3, is a sus-
ceptibility gene to SLE shared by the Caucasian and Asian
populations. Because both TNIP1 and A20 are thought to
be involved in the inhibition of NF-B activation, genetic
association of these genes implicates a causal role of NF-
B regulation pathway in the pathogenesis of SLE.
Kalergis et al. [24] demonstrated that expression of
IB-a,a ni n h i b i t o ro fN F - B, was decreased in Fcg
receptor IIb-deficient mice which present lupus-like
symptoms, and the symptoms were reduced by treat-
ment with NF-B inhibitors. Previous studies demon-
strated that TNFAIP3 risk allele rs2230926G (127Cys)
leads to reduced inhibitory activity of NF-B activation
[6] or reduced mRNA level of TNFAIP3 [10]. In view of
these observations, it is speculated that the risk allele of
TNIP1 may also be associated with reduced inhibitory
activity of TNFAIP3-TNIP1 pathway.
TNIP1 rs7708392 is located in intron 1. Expression
analysis using the GENEVAR [25] and the International
HapMap databases [26] as previously described [27] did
not show significant effect of rs7708392 genotypes on
the mRNA level of TNIP1 (data not shown). Although
the direct molecular mechanism of the risk allele to
cause SLE remains unclear, it is possible that the risk
allele may be associated with the selection of splicing
Table 2 Association study of TNIP1 rs7708392 with SLE in a Japanese population
Genotype Allele Allelic association Recessive model*
C/C C/G G/G C P OR (95%CI) P OR (95%CI)
All SLE (n = 364) 216 (59.3) 125 (34.3) 23 (6.3) 557 (76.5) 0.0022 1.40 (1.13-1.74) 0.0023 1.52 (1.16-2.00)
SLE subsets
Renal disorder + (n = 203) 126 (62.1) 68 (33.5) 9 (4.4) 320 (78.8) 0.00065 1.60 (1.22-2.10) 0.0015 1.71 (1.23-2.38)
Neurologic disorder + (n = 53) 28 (52.8) 21 (39.6) 4 (7.5) 77 (72.6) 0.55 1.14 (0.73-1.79) 0.59 1.17 (0.66-2.05)
Serositis + (n = 55) 33 (60.0) 18 (32.7) 4 (7.3) 84 (76.4) 0.16 1.39 (0.88-2.20) 0.12 1.57 (0.89-2.75)
Anti-dsDNA Ab + (n = 280) 169 (60.4) 93 (33.2) 18 (6.4) 431 (77.0) 0.0026 1.44 (1.14-1.83) 0.0021 1.59 (1.18-2.13)
Anti-Sm Ab + (n = 67) 37 (55.2) 26 (38.8) 4 (6.0) 100 (74.6) 0.26 1.27 (0.84-1.91) 0.33 1.29 (0.77-2.15)
Onset <20 yr (n = 86) 46 (53.5) 34 (39.5) 6 (7.0) 126 (73.3) 0.37 1.18 (0.82-1.70) 0.43 1.20 (0.76-1.90)
Healthy controls (n = 513) 251 (48.9) 215 (41.9) 47 (9.2) 717 (69.9) reference reference
OR: odds ratio, 95% CI: confidence interval. Genotype and allele frequencies are shown in parentheses (%).
Association was tested by c
2 analysis using 2 × 2 contingency tables. All SLE group as well as each SLE subset was compared with healthy controls.
*Association was tested under the recessive model for rs7708392C allele.
Table 3 Association study of TNIP1 rs7708392 with RA in a Japanese population
Genotype Allele Allelic Association Recessive Model*
C/C C/G G/G C P OR (95%CI) P OR (95%CI)
All RA (n = 553) 292 (52.8) 215 (38.9) 46 (8.3) 799 (72.2) 0.23 1.12 (0.93-1.35) 0.21 1.17 (0.92-1.49)
All healthy controls (n = 513) 251 (48.9) 215 (41.9) 47 (9.2) 717 (69.9) reference reference
HLA-DRB1 shared epitope positive
RA (n = 376) 203 (54.0) 142 (38.7) 31 (8.2) 548 (72.9) 0.76 1.04 (0.80-1.37) 0.57 1.11 (0.78-1.56)
Healthy controls (n = 202) 104 (51.5) 83 (41.1) 15 (7.4) 291 (72.0) reference reference
HLA-DRB1 shared epitope negative
RA (n = 171) 86 (50.3) 70 (40.9) 15 (8.8) 242 (70.8) 0.67 1.07 (0.80-1.43) 0.68 1.08 (0.74-1.58)
Healthy controls (n = 296) 143 (48.3) 125 (42.2) 28 (9.5) 411 (69.4) reference reference
OR: odds ratio, 95% CI: confidence interval. Genotype and allele frequencies are shown in parentheses (%).
Association was tested by c
2 analysis using 2 × 2 contingency tables. Comparisons were made between all RA and all healthy controls, HLA-DRB1 shared epitope
positive RA and controls, and shared epitope negative RA and controls.
*Association was tested under the recessive model for rs7708392C allele.
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have been identified [1]. Presence of alternative exon 1A
and 1B, as well as splice variants lacking exon 2, has
been described. Because rs7708392 is located between
exon 1B and exon 2, it is possible that this SNP may
influence the usage of the splicing isoform. It is also
possible that other causative SNPs in tight LD with
rs7708392 may exist. Such a possibility would be
addressed by resequencing the entire TNIP1 gene.
Interestingly, in sharp contrast to the Caucasian popu-
lations, the risk rs7708392C constituted the major allele
in the Japanese population. This resulted in substantially
higher PAR% in the latter. We previously reported simi-
lar findings in STAT4 and BLK SNPs [14,15]. In Chi-
nese, a SNP rs10036748, which is in tight LD with
rs7708392 in Japanese (r
2 = 0.81, HapMap database
[26]), has been shown to be associated with SLE. The
f r e q u e n c i e so fr s 1 0 0 3 6 7 4 8r i s ka l l e l ei nC h i n e s e( c a s e s
79.7%, controls 66.1%) [8] are similar to those of
rs7708392 in Japanese (Table 2). It should be noted
that, because the information used to estimate the PAR
% was based on the data from a variant that has not
been shown to be the causal variant in TNIP1,a n dt h e
estimates of the allele frequency and OR (as an approxi-
mation for RR) were taken from a rather small case-
control study, the PAR% values shown here represent
rough estimates. Nevertheless, the data suggest that the
significance of TNIP1 in the genetic background of SLE
may be substantially greater in the Asian than in the
Caucasian populations.
In the association analysis with the clinical subsets,
none of the case-only comparisons (cases with each clin-
ical phenotype versus those without) reached statistical
significance, partly because of the insufficient statistical
power caused by the small sample size due to stratifica-
tion. However, preferential association of TNIP1 with
renal disorder and anti-dsDNA antibody was suggested
by comparison with healthy controls. In our subjects,
preferential association with renal disorder was also
observed for TNFAIP3 [10].
On the other hand, association was not observed
with the SLE subsets having neurological disease, sero-
sitis, anti-Sm antibody and age of onset <20. It is inter-
esting to note that renal disorder and presence of anti-
dsDNA are significantly correlated in SLE, while neu-
rologic disorders are not, suggesting that these clinical
features might represent different clinical subsets of
SLE [28]. In view of this, our findings could be inter-
preted such that polymorphisms in TNIP1-TNFAIP3
p a t h w a ym i g h tp l a yas i g n i f i c a n tr o l ei nt h es u b s e to f
SLE characterized by renal disorder and anti-dsDNA
antibody, but not in the subset with neurologic disease.
Such a hypothesis should be validated in future large-
scale studies.
No strong evidence for association of rs7708392 with
RA was obtained in this study. The sample size in this
study (553 RA patients and 513 controls) provides 80%
power to detect associations with genotype relative risk
of 1.32 or greater, but we cannot rule out a possibility
of weak association. Recently published meta-analysis of
GWAS in Caucasians also failed to demonstrate statisti-
cally significant association of TNIP1 SNP with RA,
although similarly to our observation, a tendency for
association was detected [29]. Thus, while a role of
TNFAIP3 is observed both in SLE and RA genetics,
TNIP1 appears to play a major role in SLE, but not in
RA. Such a difference might possibly imply that the
molecular mechanism of TNIP1 association might not
be fully explained by A20 modification. In support of
this possibility, TNIP1 has been shown to block TNF-
induced programmed cell death in TNFAIP3 deficient
cells, indicating that TNIP1 does not always require A20
to perform its anti-apoptotic function [3]. Thus, further
analysis on the molecular mechanisms involving these
molecules is required.
Conclusions
Association of TNIP1 with SLE was confirmed in a Japa-
nese population. TNIP1 is a shared SLE susceptibility
gene in the Caucasian and Asian populations, but the
genetic contribution appeared to be greater in the
Asians because of the higher risk allele frequency in the
population. Taken together with the association of
TNFAIP3, these observations underscore the crucial role
of NF-B regulation in the pathogenesis of SLE.
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